麦克森公司 MCK

Mr. Tyler has served as chief executive officer of McKesson Corporation since 2019 and became Chair of the Board in May 2026. He previously served as the Company's president and chief operating officer from 2018 to 2019. Mr. Tyler served as chairman of the Management Board of McKesson Europe AG from 2017 to 2018, president and chief operating officer of McKesson Europe from 2016 to 2017, president of McKesson's North American Pharmaceutical Distribution and Services from 2015 to 2016, and McKesson's executive vice president, corporate strategy and business development from 2012 to 2015. Mr. Tyler previously served in various other leadership roles at McKesson, including as president of U.S. Pharmaceutical, president of McKesson Medical-Surgical, and president of McKesson Specialty Health. Mr. Tyler is a member of the board of directors of the International Federation of Pharmaceutical Wholesalers (IFPW) and a member of the IFPW Foundation board of directors. He is a member of the American Cancer Society's CEOs Against Cancer group in the North Texas chapter. Mr. Tyler earned his Ph.D. from the University of Chicago, Department of Economics specializing in industrial organization, labor economics and public finance / project evaluation. OTHER PUBLIC COMPANY BOARDS: Current: Republic Services, Inc.

Ms. Michele Lau, Executive Vice President and Chief Legal Officer since January 2024. Chief Legal Officer and Corporate Secretary, GoDaddy (technology services) from July 2021 to November 2023. Senior Vice President, Corporate Secretary and Associate General Counsel at McKesson from March 2018 to June 2021 and various other legal roles at McKesson from 2008 to 2018.

Ms. LeAnn B. Smith, Executive Vice President and Chief Human Resources Officer since December 2022. Previously, Senior Vice President, Talent Management and Development from 2021 to 2022. Chief People Leader, Global Corporate Functions for Walmart Inc. (retail) from 2018 to 2021.

Ms. Martinez most recently served as executive vice president and chief operating officer from 2021 to 2024 and was executive vice president and chief customer experience officer from 2018 until 2021 at Cisco Systems, Inc., a multinational digital communications technology company. Prior to joining Cisco, Ms. Martinez served in a variety of senior executive roles at Salesforce, Inc., including president, Global Customer Success and Latin America from 2016 to 2018; president, Sales and Customer Success from 2013 to 2016; executive vice president and chief growth officer from February 2012 to 2013; and executive vice president, Customers for Life from 2010 to 2012. Prior to joining Salesforce, she managed the global services business for Microsoft Corporation, including professional services and customer support for all products. Ms. Martinez also has held a number of other leadership positions at Motorola, Inc. and AT&T Inc., and served as chief executive officer of Embrace Networks, Inc. Ms. Martinez holds a bachelor's degree in electrical engineering from the University of Puerto Rico and a master's degree in computer engineering from Ohio State University. OTHER PUBLIC COMPANY BOARDS: Current: Bank of America Corporation, Tyson Foods, Inc., Past Five Years: Cue Health Inc. (2021 - 2024).

Ms. Doughtie is the former chair and chief executive officer of KPMG U.S., one of the largest professional services firms. She held this role from 2015 to 2020, becoming the first woman to serve as both chair and CEO in the firm's history. She also was a member of KPMG's Global Board and Executive Committee. Ms. Doughtie led KPMG's advisory business in the U.S. after joining KPMG's audit practice in 1985 and serving in a number of national, regional and global leadership roles, including as lead engagement partner. Ms. Doughtie earned a B.S. in accounting from Virginia Polytechnic Institute and State University (Virginia Tech)/Pamplin College of Business in 1985, as well as her certification as a public accountant. OTHER PUBLIC COMPANY BOARDS: The Boeing Company, Workday, Inc.

Dr. Gerberding currently serves as the chief executive officer of the Foundation for the National Institutes of Health (FNIH) and has held this role since 2022. The FNIH convenes public and private partnerships between the National Institutes of Health, academia, life science companies and patient advocacy groups. Previously, Dr. Gerberding served as the executive vice president and chief patient officer at Merck & Co. from 2014 to 2022, overseeing patient engagement, strategic communications, global public policy and population health. She joined Merck in 2010 as the president of vaccines and was instrumental in expanding global access to the company's vaccines. Dr. Gerberding served as the director of the Centers for Disease Control from 2002 to 2009. Dr. Gerberding serves on the board of directors of the National Health Council and the Mayo Clinic, and she is on the board of trustees for Case Western Reserve University, where she serves on the Research and Tech Transfer Committee. Dr. Gerberding received her undergraduate and medical degrees from Case Western Reserve University and a Masters of Public Health at the University of California, Berkeley. OTHER PUBLIC COMPANY BOARDS: Past Five Years: Cerner Corporation (2017 - 2022), HilleVax, Inc. (2021 - 2025).

Ms. Wilson-Thompson most recently served as executive vice president and global chief human resources officer of Walgreens Boots Alliance, Inc., a healthcare and retail pharmacy company, from 2014 to 2021, after serving as senior vice president and chief human resources officer from 2010 to 2014. Previously, she served as senior vice president, global human resources and chief labor and employment counsel at Kellogg Company. Ms. Wilson-Thompson earned an A.B. degree from the University of Michigan, and J.D. and LL.M. (Corporate and Finance Law) degrees from Wayne State University. OTHER PUBLIC COMPANY BOARDS: Current: Tesla, Inc., Wolverine Worldwide, Inc.

Dr. Dunsire served as president and chief executive officer of H. Lundbeck A/S, a biopharmaceutical company specializing in developing and delivering transformative therapies for brain diseases, from 2018 to 2023. From 2017 to 2018, she served as president and chief executive officer of XTuit Pharmaceuticals, a biopharmaceutical company focused on cancer treatments. Prior to her employment with XTuit Pharmaceuticals, Dr. Dunsire held various executive leadership roles at FORUM Pharmaceuticals, Millennium: The Takeda Oncology Company and Millennium Pharmaceuticals. Dr. Dunsire started her career as a primary care physician in Johannesburg, South Africa and received her medical degree from the University of Witwatersrand in Johannesburg, South Africa. OTHER PUBLIC COMPANY BOARDS: Current: Ultragenyx Pharmaceutical Inc., Past Five Years: Alexion Pharmaceuticals Inc. (2018 - 2021), Syros Pharmaceuticals, Inc. (2021 - 2024).

Ramesh Srinivasan serves as Executive Vice President and Chief Strategy Officer at McKesson Corporation, leading long-term strategic planning and business development as of August 2026. Prior to this role, he led strategic pricing and manufacturer relations, overseeing the Cell, Gene, and Advanced Therapies segment, with an educational background from the California Institute of Technology.

Mr. Kenny K. Cheung joined McKesson as Executive Vice President and CFO, effective May 29, 2026. Cheung joins McKesson from Sysco, where he served as Executive Vice President and Chief Financial Officer, overseeing global financial planning and analysis, accounting, audit, tax, and corporate finance.

Francisco J. Fraga, Executive Vice President, Chief Information Officer and Chief Technology Officer since September 2023; Senior Vice President and Chief Information Officer, U.S. Pharmaceutical from 2021 to 2023. Previously, Chief Technology and Information Officer for Campbell Soup Company, Inc. (branded food manufacturer) from 2017 to 2021.

On February 21, 2022, Napoleon B. Rutledge, Jr. was appointed as Senior Vice President, Controller and Chief Accounting Officer of McKesson Corporation, for the term of office provided by Article IV of the Company's By-Laws. Before joining the Company effective March 1, 2022, Mr. Rutledge worked for Genuine Parts Company (GPC), a distributor of automotive and industrial replacement parts, from 1999 to February 2022, holding leadership roles in corporate finance, treasury, risk management, audit and SEC reporting. He most recently served as GPC's Senior Vice President of Finance and Chief Accounting Officer and was responsible for regulatory accounting matters, financial reporting, financial planning and analysis and accounting policies. Earlier in his career, Mr. Rutledge worked in public accounting with Ernst & Young.